spacer
home > ebr > autumn 2009 > the end of the line for paper
PUBLICATIONS
European Biopharmaceutical Review

The End of the Line for Paper

 

The biopharmaceutical environment is highly regulated, and therefore necessitates effective document management processes. In addition to the strict regulatory environment, which encompasses pharmaceutical documentation, organisations operating in this sector must also find ways of processing an increasing volume of information. Additionally, sponsor organisations must comply with increasing regulatory demands, particularly with respect to electronic submissions for approval.

To manage data efficiently, many companies are implementing electronic document management systems (eDMS) to assist in the storage and organisation of electronic records. The document lifecycle is controlled so that periodic reviews, regulatory changes and design modifications to the installed manufacturing plant, lab equipment and clinical trials, as well as re-training and assessment of operators, can all be managed within one seamless system. These systems are used for managing both digital and printed documents (once scanned in), and are flexible enough to allow existing documentation to be incorporated into the system while enabling full compliance with current regulatory standards. This article will discuss the increasing need for effective document management strategies within the pharmaceutical industry, the regulatory issues affecting pharmaceutical document management and the growing use of eDMS, in particular for biotech companies wth limited resources, both to purchase software, validate it and maintain it.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Keith Williams founded Good Products in 2006. Keith has many years of biopharmaceutical consultancy experience, particularly in computer systems validation, and computerised systems training in manufacturing, clinical and laboratory environments. He has a BSc in Genetics and Microbiology and an MSc in Biochemical Engineering.

Patrick Hughes joined Good Products in 2007 and is Senior VP, Strategic Business Development. Previously, Patrick worked for the clinical technology organisation, ClinPhone plc, in various senior management roles including sales and marketing, product management and strategic business development. These roles focused on the commercial management and strategic direction of IVR, ePRO, EDC, patient recruitment and CTMS technologies.

spacer
Keith Williams
spacer
spacer
spacer
Patrick Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement